2 High-Growth Stocks That Could Explode in the Next Decade

The S&P/TSX Composite Index fell 10 points on April 25. The Index has still climbed 15.7% in 2019 so far. Investors have had their faith rewarded to start 2019, but those with their eyes on long-term gains should be thinking about what stocks will be high performers in the 2020s.

Today, we are going to look at two stocks that have enjoyed huge gains over the past year. Both stocks are players in fast-growing industries. Let’s see why these high-growth equities are great bets to continue surging in the coming years.

Aurora Cannabis (TSX:ACB)(NYSE:ACB)

Aurora Cannabis is one of the largest cannabis producers in Canada. Shares have climbed 80.2% in 2019 as of close on April 25. The stock is up 56% over the past year. Last month, I discussed how the addition of Nelson Peltz as a strategist had the potential to vault Aurora to the top of the cannabis pack in Canada.

Aurora is set to release its fiscal 2019 third-quarter results next month. The first batch of earnings for top producer Aphria were extremely disappointing. The bears are coming out for cannabis stocks this spring, and there are concerns that Aurora and other top producers are also in for a rough patch. An earnings miss can create buying opportunities for investors looking to dip into this young sector. Aurora is well worth monitoring ahead of its next report.

However, looking long, Aurora is a solid add at its current price. The company has made impressive strides in securing international partnerships and it has established itself as a production behemoth in Canada. Its production ramp-up is expected to result in a spike in revenues in the final quarter of this fiscal year. Aurora looks poised to be a big domestic and international player in this new and booming sector.


Zymeworks is a Vancouver-based clinical-stage company focused on multifunctional biotherapeutics. It has entered two product candidates into clinical trials: ZW25 and ZW49. In January, I explained why Zymeworks has enormous potential if it brings ZW25 to market.

The global breast cancer drug market will be worth $38.4 billion by 2025, according to a recent report from Grand View Research. This represents a compound annual growth rate (CAGR) of 10.7% from 2019 to 2025.

On April 15, Zymeworks announced that it had initiated its global multi-centre Phase II clinical trial evaluating its antibody ZW25. This two-part open-label study will aim to confirm the safety, tolerability, and anti-tumour activity of ZW25 in combination with standard care regimens. This is a big and exciting step for Zymeworks.

Market reactions to Zymeworks’s progress has historically been slow. Investors seemed to finally catch up to the news this week. Shares climbed 11% week over week as of close on April 25. Zymeworks has made solid progress, but it remains a speculative buy in late April. It is projected to generate negative EBITDA in the $20-25 million range in fiscal 2019. Not surprisingly, the company has ramped up research and development spending.

You might be missing out on one of the biggest opportunities in Canadian investing history…

Marijuana was legalized across Canada on October 17th, and a little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

Besides making key partnerships with Facebook and Amazon, they’ve just made a game-changing deal with the Ontario government.

One grassroots Canadian company has already begun introducing this technology to the market – which is why legendary Canadian investor Iain Butler thinks they have a leg up on Amazon in this once-in-a-generation tech race.

This is the company we think you should strongly consider having in your portfolio if you want to position yourself wisely for the coming marijuana boom.

Learn More About This TSX Stock Now

More reading

Fool contributor Ambrose O’Callaghan has no position in any of the stocks mentioned.

Source: The Fool
2 High-Growth Stocks That Could Explode in the Next Decade
The Fool

The Motley Fool
Contributor for investorsnews.ca
The Motley Fool is dedicated to helping the world invest — better. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, mutual funds, and premium investing services.

In all we do, we take a different approach.

We believe – and have proven over decades – that the individual investor can beat the market.

We believe that anyone can do it, even if they don’t have a lot of time or money to devote to investing.

We believe in a long-term outlook, helping people build wealth over time.

We believe that the person best positioned to take care of your financial future is you.

And we work tirelessly on behalf of our hundreds of thousands of members who are enjoying the opportunities that come with having enough money to do the things that matter to them.

While we are headquartered in Alexandria, Va., The Motley Fool advocates for the individual investor around the globe with offices in the UK, Australia, Canada, Singapore, and Germany.

Related posts